Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391778 · ClinicalTrials.gov registry record · Phase 1
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
A Phase 1 study of Neoplasms, sponsored by Uswm CT.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT03391778 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Uswm CT. The registered enrollment target is 250 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT03391778, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Uswm CT.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Conditions Studied
Interventions
- BIOLOGICAL ADP adoptive cell therapy
Study Locations (20)
Maryland
- ADP Investigational Site - Baltimore
- National Cancer Institute - Center for Cancer Research - Bethesda
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Georgia
- Emory University School of Medicine - Atlanta
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University School of Medicine in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03391778
The ClinicalTrials.gov registry entry for NCT03391778 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ADP adoptive cell therapy is the first listed.
NCT03391778 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Maryland, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT03391778 about?
NCT03391778 is a clinical study titled "Adoptive Cell Therapy Long-term Follow-up (LTFU) Study". This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
What is the current status of trial NCT03391778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2018-04-09. Estimated completion is 2032-04-01.
What conditions does trial NCT03391778 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03391778?
The interventions under investigation include: ADP adoptive cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03391778?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03391778 being conducted?
This trial has 20 study locations across Georgia, Maryland, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.